热门资讯> 正文
罗氏将肥胖资产CT-388转入第三阶段
2025-09-23 00:12
- 团车网(TC) 0
- 罗氏(ADR)(RHHBY) 0
- 伙伴全球(GLP) 0
- Roche (OTCQX:RHHBY) has advanced CT-388, a dual GLP-1 and GIP receptor agonist/modulator, into phase 3.
- The announcement was made during Roche Pharma Day in London on Monday.
- "Our goal is to become a Top 3 player (in the obesity drug market), and I want you to know I'm serious about this goal," Roche Pharmaceuticals CEO Teresa Graham said, Reuters reported.
- During her presentation, Graham noted that the company has six assets in the pipeline for obesity and conditions linked to it, such as type 2 diabetes, adding they could all hit the market by 2030, with some potentially becoming blockbusters.
- In March, Roche signed a licensing deal with Zealand Pharma (OTCPK:ZLDPF) to co-develop and co-commercialize the latter's petrelintide, an amylin analog, as a standalone therapy and a fixed-dose combination with CT-388.
- The Swiss pharma acquired CT-388 through its September 2024 acquisition of Carmot Therapeutics.
More on Roche
- Roche Holding AG (RHHBY) Special Call - Slideshow
- Roche's 89bio Buyout: Building A Combo-Ready Metabolic Franchise Beyond GLP-1 Wars
- 89bio: Pegozafermin MASH Drug Advancement Nets Roche Acquisition
- Roche says breast cancer drug combo including giredestrant met main goals in late stage trial
- Key deals this week: Brighthouse Financial, Workday, Paramount Skydance, Radian Group, Roche and more
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
